Blog
What the GLP-1 and sleep studies actually found, what they don't establish, and where the marketing tends to stretch past the data. General information only, not medical advice.
- GLP-1 October 30, 2026 6 min read
A Daily Pill Kept More Weight Off After People Stopped Injectable GLP-1s. Here Is What the 52-Week Trial Cannot Tell You.
The ATTAIN-MAINTAIN trial tested whether switching to an oral GLP-1 slows regain after semaglutide or tirzepatide. The comparison is real, but the placebo arm, the sample, and the branded-product question all limit what it means.
- GLP-1 October 28, 2026 6 min read
Women on Menopause Hormone Therapy Lost More Weight on Semaglutide in a Mayo Clinic Study. Here Is What It Cannot Show.
A retrospective analysis of more than 3,800 women found a 1.5-point gap in weight loss at one year between semaglutide users with and without hormone therapy. Here is what that gap is, and why it does not mean hormone therapy boosts weight loss.
- GLP-1 October 26, 2026 6 min read
People Who Switched From GLP-1 Injections to a Pill Averaged a 4.1% Weight Change in 3 Months. Here Is What That Study Cannot Tell You.
A Novo Nordisk-announced analysis presented at EASD 2026 followed 194 telehealth patients who moved from injectable semaglutide or tirzepatide to the Wegovy pill. Here is what it measured, and why it cannot say whether switching is a good idea.
- GLP-1 October 23, 2026 6 min read
An Oral GLP-1 Matched Insulin on Heart Safety in a 2,749-Person Trial. The Headline Death-Rate Number Is the Weakest Part.
Lilly's ACHIEVE-4 trial tested orforglipron against insulin glargine in people with type 2 diabetes and heart or kidney disease. Here is what "noninferior" means, and why the 57% lower death figure is a hypothesis rather than a finding.
- GLP-1 October 21, 2026 6 min read
GLP-1 Users Had Fewer Heart Complications and Infections After Surgery in a 2-Million-Patient Study. Here Is What It Cannot Tell You.
A large analysis presented at ANESTHESIOLOGY 2026 tied GLP-1 use to lower odds of postoperative heart events and infections. Here is what the numbers show, and why an observational match is not a reason to change anything before an operation.
- GLP-1 October 19, 2026 6 min read
Tirzepatide Matched Dulaglutide on Heart Outcomes in a 13,000-Person Trial. "Noninferior" Does Not Mean "Better."
The SURPASS-CVOT trial compared tirzepatide with dulaglutide in adults with type 2 diabetes and heart disease. Here is what the headline result says, what "noninferior" means, and who the trial leaves out.
- GLP-1 October 16, 2026 6 min read
People Who Lost More Weight on GLP-1s Had Lower Rates of Four Chronic Conditions. Here Is What That Association Does Not Prove.
A real-world analysis of nearly 90,000 US adults linked bigger first-year BMI reductions on GLP-1 medications to lower rates of osteoarthritis, kidney disease, and sleep apnea. Here is how to read it, and why it is not a forecast for any individual.
- GLP-1 October 14, 2026 6 min read
GLP-1s Were Tied to Fewer Liver Complications in Adults Over 65 With Fatty Liver Disease. Here Is What the Study Can and Cannot Tell You.
A Houston Methodist analysis of nearly 88,000 older adults with fatty liver disease linked GLP-1 therapy to lower rates of liver decompensation and death. Here is what it found, and why an observational study of this size still leaves the key question open.
- GLP-1 October 12, 2026 6 min read
Meals or an App Slowed Weight Regain After People Stopped a GLP-1. The Trial Had 39 People.
A small randomized pilot from Tufts found that home-delivered meals or a coaching app were tied to less weight regain in the four months after stopping a GLP-1. Here is what it found, and why a pilot this size is a starting point, not an answer.
- GLP-1 October 9, 2026 6 min read
Survodutide Cut Weight by 12–13% in a Phase 3 Trial. The Headline Number Depends on How You Count.
The full SYNCHRONIZE-1 results for survodutide, an investigational dual-hormone injection, are now in NEJM. Here is what the trial found, why the estimand matters, and what it cannot tell you about any compounded medication.
- GLP-1 October 7, 2026 6 min read
A Lilly-Linked Analysis Says an Oral GLP-1 Worked at Every Stage of Menopause. Here Is What a Post Hoc Subgroup Can and Cannot Show.
A new analysis of two phase 3 orforglipron trials split results by menopausal status. It is a useful signal for a question that often gets skipped, and a weaker one than the headline suggests.
- GLP-1 October 5, 2026 6 min read
Does Semaglutide Cost You Muscle? A 12-Month Study Measured It. Here Is What It Can and Cannot Tell You.
The SEMALEAN study tracked body composition in 106 people on semaglutide for a year. Fat mass fell, lean mass dipped and then leveled off, and grip strength improved. Here is what that does and does not establish.
- GLP-1 October 4, 2026 6 min read
Semaglutide Slowed "Biological Aging" Clocks in a Randomized Trial. Here Is What a Clock Is, and Is Not.
A Nature Communications trial found semaglutide shifted several epigenetic aging measures over 32 weeks. The headline is real, but the participants, the endpoint, and the analysis plan all limit what it can tell you.
- GLP-1 September 30, 2026 6 min read
What Happens After You Stop a GLP-1? A Cambridge Analysis Put a Curve on Weight Regain
A March 2026 meta-regression pooled six randomized trials to model how quickly weight returns after GLP-1 treatment ends. Here is what the curve shows, what it leaves out, and why it is a reason to plan rather than a verdict.
- GLP-1 September 28, 2026 6 min read
A New Study Says BMI Cutoffs Miss Half the People With Elevated Heart Risk. Here Is What It Did Not Test.
Researchers presenting at EASD 2026 found that about half of adults with a BMI of 25–26.9 carry cholesterol or inflammation markers tied to heart risk comparable to people who meet current GLP-1 criteria. Here is what that shows, and why it is not evidence that treating them would help.
- GLP-1 September 25, 2026 7 min read
A New Review Pooled 38 GLP-1 Trials in People Without Diabetes. Here Is What the Numbers Can and Cannot Tell You.
A September 2026 systematic review in Annals of Internal Medicine updated the evidence on GLP-1 medications for adults with overweight or obesity and no diabetes, adding 14 new trials. Here is what it found, what "placebo-subtracted" means, and why a trial range is not a forecast for any one person.
- GLP-1 September 23, 2026 6 min read
Five Studies Tied GLP-1s to Lower Cancer Rates. Researchers Are Now Planning the Trial That Could Actually Test It.
Observational studies presented at ASCO 2026 linked GLP-1 prescriptions to lower rates of breast, lung, liver, and blood cancers. Here is what those numbers show, why the researchers themselves call them associations, and what the planned INSPIRE trial is designed to answer.
- GLP-1 September 21, 2026 6 min read
Retatrutide Posted 28% Average Weight Loss in a Phase 3 Trial. Here Is What That Number Is, and Is Not.
Eli Lilly reported topline phase 3 results for retatrutide, an investigational triple-hormone drug. Here is how to read the headline figure, what the trial does not establish, and why it says nothing about any compounded medication.
- GLP-1 September 19, 2026 6 min read
GLP-1 Plus Healthy Habits Was Tied to Lower Heart Risk in a 98,000-Veteran Study. Here Is What That Does and Does Not Mean.
A Lancet Diabetes & Endocrinology cohort study found that GLP-1 use and healthy habits were each linked to fewer cardiovascular events, and the combination to fewer still. Here is what the design can and cannot tell you.
- GLP-1 September 16, 2026 8 min read
Tirzepatide Beat Semaglutide for Weight Loss in a New Meta-Analysis. It Also Had More Serious Side Effects.
A September 2026 meta-analysis of 41,381 patients found tirzepatide produces more weight loss than semaglutide — and a higher rate of serious adverse events. Here is what the tradeoff does and does not tell you.
- Industry September 14, 2026 8 min read
The Endocrine Society Just Told Researchers to Stop Grading GLP-1s on the Scale Alone
A September 2026 scientific statement reviewing 200+ studies argues that percent body weight lost is an incomplete way to judge whether obesity treatment is working — and flags how little is actually known about why people respond so differently.
- Sleep September 11, 2026 8 min read
A Once-Daily Pill for Sleep Apnea Cleared a Phase 3 Trial. It Is Not Approved Yet, and It Is Not for Everyone.
AD109, an investigational oral medication for obstructive sleep apnea, cut breathing interruptions by roughly 44% in a 646-person trial. Here is what the SynAIRgy results show, what the FDA still has to decide, and what a device that measures your own AHI can tell you that a trial average cannot.
- GLP-1 September 9, 2026 7 min read
A New Study Links Semaglutide to 40% Fewer Asthma Attacks. Here Is What It Doesn't Establish.
Researchers at Imperial College London reported a large drop in asthma and COPD flare-ups among semaglutide users. The data is real. It is also a conference abstract from an observational study, not proof the drug treats lung disease.
- GLP-1 September 8, 2026 8 min read
A New Nature Study Found Semaglutide Extends Lifespan in Mice. Here's What It Doesn't Prove.
A September 2026 Nature paper found that late-life semaglutide treatment extended lifespan in female mice by 12%. Here is what the study actually measured, why "anti-aging drug" is not the right takeaway yet, and what none of it says about compounded semaglutide.
- GLP-1 September 4, 2026 8 min read
A Major Physician Group Just Ranked GLP-1s First-Line for Obesity. Here Is What That Ranking Actually Decides.
The American College of Physicians named semaglutide and tirzepatide first-line obesity medications in a new living guideline. Here is what the four-tier ranking covers, what the guideline itself says is still unresolved, and why "first-line" is not the same as "right for you."
- GLP-1 September 2, 2026 8 min read
A Gut Hormone Subtype Predicted Who Loses Twice as Much Weight on Tirzepatide
A Mayo Clinic study found that roughly one in four adults with obesity has a distinct gut-hormone profile linked to nearly double the weight loss on tirzepatide. Here is what the physiology shows, why the test behind it is not something you can order today, and what that means if you are on a GLP-1 and not seeing that result.
- GLP-1 August 31, 2026 7 min read
A New Mouse Study Says Semaglutide Protects Knee Cartilage. Even Without Weight Loss
A March 2026 Cell Metabolism study found semaglutide slowed cartilage damage in mice even when weight loss was blocked. Here is how that fits with the human knee-osteoarthritis trial data, and what a mouse mechanism still has to prove.
- GLP-1 August 28, 2026 8 min read
Semaglutide "Beat" Tirzepatide by 57% in a New Study, and the Company That Makes Semaglutide Funded and Wrote It
A large real-world study found semaglutide cut cardiovascular risk far more than tirzepatide in people with obesity and heart disease. Every author was a Novo Nordisk employee. Here is what the data shows and what industry funding means for how to read it.
- Sleep August 26, 2026 8 min read
Tirzepatide Got Approved for Sleep Apnea in Late 2024. New Data Shows Who Actually Gets It.
A claims-data analysis of nearly 20 million adults with obstructive sleep apnea and a peer-reviewed sleep-clinic study both point to the same gap: most people who could qualify for a GLP-1 for OSA are not on one, and insurance status predicts who is.
- GLP-1 August 24, 2026 7 min read
What Happens to Your Weight Loss in Year Two on a GLP-1? New Data, With a Catch
Two new studies of 63,000+ patient records find most people who stay on a GLP-1 keep their weight loss into year two. The catch is in who made it into the dataset at all.
- GLP-1 August 21, 2026 7 min read
A Randomized Trial Tested Semaglutide for Alcohol Use Disorder. Here's What It Actually Found
A Lancet-published, placebo-controlled trial found semaglutide reduced heavy drinking days more than placebo in people with alcohol use disorder and obesity. Here is what the data shows, and why it is narrower than the headlines suggest.
- Sleep August 19, 2026 7 min read
GLP-1s, SGLT2 Inhibitors, or Exercise for Sleep Apnea? A New Comparison Answers Less Than the Headline Suggests
A network meta-analysis published August 17 ranks GLP-1 medications above SGLT2 inhibitors and aerobic exercise for reducing sleep apnea severity. The authors themselves call the ranking hypothesis-generating, not a treatment recommendation. Here is why.
- GLP-1 August 17, 2026 7 min read
GLP-1s Don't Just Silence Hunger Neurons. A New Study Says They Recruit Them
A Yale mouse study published in PNAS challenges the standard explanation for how GLP-1 medications produce weight loss, and offers a possible biological reason some patients plateau or regain. Here is what the experiment showed, and why it is not yet a finding about people.
- GLP-1 August 14, 2026 7 min read
A New GLP-1 Pill Posted ~11% Weight Loss in Trials. Here's What Phase 2b Actually Means
Aleniglipron, an oral small-molecule GLP-1 candidate, published phase 2b results showing up to 11.3% placebo-adjusted weight loss. Here's what the trial found, what phase 2b does not establish, and how it relates to the compounded medications NoBsRx provides access to.
- GLP-1 August 12, 2026 7 min read
A New Study Tracked Fitbit Data on GLP-1 Users. Activity Went Down, Not Up
A retrospective study of 753 GLP-1 users with wearable-device data found daily steps and moderate activity minutes fell after starting the medication, with no evidence that weight loss led people to move more. Here is what the data shows and why that matters for muscle, not just the scale.
- Sleep August 10, 2026 8 min read
Sleep Apnea Cases Are Projected to Grow 35% by 2050, and GLP-1s Barely Move the Number
A Lancet Respiratory Medicine model projects nearly 77 million US adults will have obstructive sleep apnea by 2050. The same model found widespread GLP-1 use would cut that by less than 5%. Here is why, and why most of the 83 million who already have it don't know it.
- GLP-1 August 5, 2026 8 min read
Is There a "Best" GLP-1? A New Study Says That's the Wrong Question
A July 2026 analysis pooled 19 trials into a new scoring system comparing GLP-1 drugs and doses on heart and metabolic health, not just weight loss. Here is what the numbers show, why comparing across separate trials is not the same as testing head-to-head, and what none of it tells you about a compounded version.
- GLP-1 August 3, 2026 8 min read
Can GLP-1s Curb Addiction? A Huge Veteran Study Says Maybe. Carefully
A cohort study of 600,000+ veterans found GLP-1 medications associated with lower rates of substance use disorders, from alcohol to opioids. Here is what the data shows, what the researchers themselves flagged as limits, and why a trial is now underway to actually test it.
- Sleep August 2, 2026 7 min read
GLP-1s and Sleep Apnea: What the New Research Actually Says
A large July 2026 study links GLP-1 prescriptions to lower cardiovascular event rates in people with obstructive sleep apnea. Here is what it found, what it did not find, and why none of it tells you your own numbers.
